Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alkermes, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Are at least 18 years of age at time of consent
Have a body mass index (BMI)of 19 to 35 kg/m2 at screening
Are receiving prescribed opioid medication for the management of chronic, non-cancer pain
Meet the criteria of OIC
Agree to use an acceptable method of contraception for the duration of the study
You may not be if
Pregnancy and/or currently breastfeeding
Clinically significant medical condition or illness (other than the condition for which the pain medication is being prescribed)
Receiving treatment with opioid therapy for cancer-related pain, abdominal pain, scleroderma, and/or for the management of drug addiction
Any gastrointestinal (GI) disorder (other than opioid-induced constipation) or GI structural abnormality known to affect bowel transit, produce GI obstruction, or contribute to bowel dysfunction
Use of naloxone, Subutex or Suboxone, Revia, Relistor, or Entereg starting 15 days before the first study visit following screening until the end of the study
Participation in a clinical trial of a pharmacological agent within 30 days before screening
Clareo Health | ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
